Comparative Pharmacology
Head-to-head clinical analysis: CLOFARABINE versus FLUDARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOFARABINE versus FLUDARA.
CLOFARABINE vs FLUDARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
None Documented
None Documented
Clinical Note
moderateClofarabine + Digoxin
"Clofarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFludarabine + Digoxin
"Fludarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateClofarabine + Digitoxin
"Clofarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFludarabine + Digitoxin
"Fludarabine may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Fludarabine phosphate: 0.7-1 h (rapid dephosphorylation). Active metabolite 2-fluoro-ara-A: terminal t1/2 20-30 h (up to 40 h in renal impairment).
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Renal: 60% excreted unchanged in urine; biliary/fecal: <5% as metabolites.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent